Overview

Gender

female

Investor Type

Investment Partner

Karen provides support to Ysios, particularly for identifying and evaluating investment opportunities.Karen serves on board of Cardoz.In addition to her role at Ysios, Karen works with several biotechnology companies as an independent consultant in business development and licensing.Prior to joining Ysios, Karen was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland, where, in Roche’s Global Research Function, she was responsible for securing numerous critical technologies for drug discovery as well as compounds for treatment of oncological and viral diseases. Among other transactions, Karen was project leader for the Alnylam-Roche collaboration announced in July 2007, valued at over $1 billion and one of Allicense’s Key Deals of the year.

She joined Roche from GLYCART, where she had worked together with Ysios colleague Joël Jean-Mairet. At GLYCART, Karen was responsible for business development, negotiating key in- and outlicensing agreements and contributing to the sale of the company to Roche in 2005. From 2001 to 2004, Karen was a Business Development Director for Ingenium Pharmaceuticals in Munich. Before that, she worked as a consultant and was a member of McKinsey & Company’s Global Healthcare Practice.

Karen holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.